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ABSTRACT 
Cholesterol-Lowering of Pantethine 
is Due to the Hydrolysis 
Product Cysteamine 
by 
Caran Graves, Master of Science 
Utah State University, 1987 
Major Professor: Dr. Carol T. Windham 
Department: Nutrition and Food Sciences 
Pantethine, a precursor of coenzyme A, has been 
shown to reduce serum cholesterol levels in 
hypercholesterolemic rabbits. The enzyme pantetheinase 
rapidly hydrolyzes pantethine to the vitamin 
pantothenic acid and the amino thiol cysteamine. 
This study was designed to compare the effect of 
cysteamine and pantothenate supplementation with that 
of pantethine on hypercholesterolemic rabbits. New 
Zealand white rabbits were fed a 0.5% cholesterol diet 
for 5 weeks; treatment groups received only the high 
cholesterol diet (control), or a high cholesterol diet 
supplemented with 1% pantethine, or an equimolar amount 
of pantothenic acid or cystamine (the disulfide of 
cysteamine). Blood samples were drawn weekly and total 
serum cholesterol levels analyzed enzymatically. 
Pantethine and cystamine both significantly reduced 
vi 
serum cholesterol levels (p < 0.05); pantothenic acid 
had no effect. Separation of serum lipoproteins using 
a preparative ultracentrifuge showed an increase in 
very low density, intermediate density and low ctensity 
lipoproteins. 
A second experiment was conducted to compare the 
effect of cystamine with other small thiols; the 
protocol was similar to the first experiment with 
treatment groups consisting of a high cholesterol 
control, cystamine, cystine or 2,hydroxyethyl 
disulfide. There was no significant reduction in serum 
cholesterol levels between tre a tment groups, although 
the cystamine supplemented group tended to be lower 




Cholesterol and Coronary Artery Disease 
Coronary heart disease is the leading cause of 
death in the United States. Recent estimates indicate 
that 5.4 million Americans have symptomatic coronary 
heart disease (American Medical Association, 1985; 
Levy, 1986). While many factors have been associated 
with heart disease, high serum cholesterol levels are 
consistently identified with increased risk of 
developing coronary heart disease (Wilhelmset et al., 
1973; Wright and Fredrickson, 1970; Keys, 1980). 
Epidemiological studies show that the chance of 
developing coronary heart disease rises as serum 
cholesterol and low density lipoprotein (LDL) levels 
rise. The 20 year report (Kagan et al., 1962) of the 
Framingham Study noted that increasing serum 
cholesterol levels correlated with an increased 
incidence of coronary heart disease; participants with 
total serum cholesterol levels over 260 mg/dl had the 
greatest risk. The Seven Countries Study (Keys, 1980), 
involving over 10,000 men from Finland, Greece, Japan, 
Yugoslavia, Italy, Netherlands, and the United States, 
found that the incidence of coronary disease was 
directly related to increased serum 9holesterol levels. 
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A prospective study of 855 Swedish men also identified 
high serum cholesterol levels ( < 270 mg/dl) as a 
significant risk factor for coronary heart disease 
(Wilhelmset et al., 1973). 
Recent clinical trials demonstrate the benefits of 
reducing serum cholesterol levels. The Leiden 
Intervention Trial (Arntzenius et al., 1985) reduced 
serum cholesterol levels by 10% over a two year period 
with dietary modifications. Coronary lesion growth 
(measured by coronary angiography) diminished 
-
significantly during this period and correlated with 
decreased serum cholesterol levels. 
The Lipid Research Clinics Coronary Primary 
Prevention Trials (1984a, 1984b) used the bile acid 
sequestrant cholestyramine to study the effects of 
reduced serum cholesterol levels on serum lipids. 
Cholestyramine treatment was associated with an average 
reduction in serum cholesterol and LDL cholesterol of 
13.4 and 20.3%, respectively. There was a 19% decrease 
in the occurrence of coronary heart disease death or 
non-fatal myocardial infarction associated with 
cholestyramine use. 
Current epidemiological and clinical data indicate 
a strong correlation between high serum cholesterol 
levels and coronary heart disease. On the basis of 
this evidence the National Institutes of Health 
/ 
(Consensus Development Conference, 1985) and American 
Heart Association (1984) recommend that the people of 
the United States actively try to reduce their risk 
factors for developing cardiovascular diseases, 
including reduction of serum cholesterol and LDL 
cholesterol levels. Aggressive treatment is 
recommended for those with serum cholesterol levels 
above the 90th percentile of the population. While 
dietary modifications may suffice for the majority, the 
use of therapeutics may be needed for high risk 
individuals (Levy, 1980; American Heart Association, 
1983; Hoeg et al., 1986). 
The major pharmacological treatments of 
hypercholesterolemia are bile-acid sequestrants and 
nicotinic acid (Levy, 1980; DeGraph, 1984; Hodges & 
Smith, 1984). These drugs reportedly decrease 
cholesterol levels 10% to 15% but have unpleasant side 
effects (Levy, 1980). Other therapeutic agents 
available in the U.S. include probucol and clofibrate; 
clofibrate lowers triglyceride levels but has limited 
effect on serum cholesterol. Pantethine, a derivative 
of the vitamin pantothenic acid, is being studied in 
Italy as a hypocholesterolemic agent (Maggi et al., 
1982; Angelico et al., 1983); it is marketed as a 
hypolipidemic agent, Pantosin (Daiichi Seiyaku Co, 
Tokyo, Japan), in Japan. 
3 
Pantethine and its Metabolites 
Pantetheine, the sulfhydryl form of pantethine, 
is composed of the vitamin pantothenic acid and the 
disulfide of the aminothiol, cysteamine. ·Pantetheine 
functions as the working arm of Coenzyme A and acyl 
carrier protein; as such, pantetheine is widely 
involved in the metabolism of carbohydrates, fat and 
proteins; cholesterol synthesis directly involves 
pantetheine (Abiko, 1975). The sulfhydryl moiety of 
cysteamine is the active site of the CoA molecule. 
Pantethine and Serum Cholesterol 
Human and animal studies show that pantethine 
treatment lowers serum cholesterol levels. Cattin and 
colleagues (1985) compared pantethine treatment with 
fenofibrate, a hypercholesterolemic drug, and found a 
comparable hypocholesterolemic effect. Hyperlipidemic 
patients given pantethine showed a 12% reduction in 
total serum cholesterol and a 33% decrease in serum 
triglycerides, but no changes in HDL cholesterol levels 
(Angelico et al., 1983). Other researchers report 
similar findings with hyperlipidemic diabetic patients 
(Miccoli et al., 1984) and dialysis patients (Donati 
et al., 1986). 
Recent reports indicate that pantethine alters 
lipid profiles in cholesterol fed rabbits. Tomikawa and 
4 
colleagues (1982) fed rabbits a diet containing 0.53 
cholesterol supplemented with 13 pantethine; control 
rabbits received a high cholesterol diet only. Total 
serum cholesterol and LDL cholesterol levels of 
pantethine supplemented rabbits decreased significantly 
(723 and 583 , respectively) after 4 weeks; very low 
density lipoprotein cholesterol was normalized, and 
high density lipoprotein cholesterol increased. These 
results were confirmed by Carrara and colleagues (1984) 
who also noted a decrease in the severity of 
atherosclerotic lesion formation in the pantethine fed 
rabbits. 
Comparison of pantethine treatment with the 
hypocholesterolemic drug, probucol, shows that both are 
effective in lowering serum cholesterol levels (Tawara 
et al., 1986). The cholesterol-lowering effect was 
even more pronounced when these compounds were used 
simultaneously. 
Oral administration of pantethine (70 to 1000 
mg/kg/day) to cystinotic patients did not result in 
detectable levels of serum pantethine up to five hours 
after treatment (Wittwer et al., 1985). Serum levels 
of pantothenic acid and cysteamine did increase with 
pantethine administration. Blood samples from rats 
taken 30 minutes after intravenous administrations of 
pantethine showed over 50 percent present as free 
5 
pantothenic acid (Ono et al., 1974). 
The enzyme pantetheinase hydrolyzes pantethine to 
pantothenic acid and cysteamine (Wittwer et al., 1983; 
Abiko, 1975). Pantetheinase activity has been 
identified in horse and pig kidney, rat liver and human 
serum (Abiko, 1975; Dupre and Cavallini, 1979; Wittwer 
et al. 1983, Wittwer et al., 1985). Rapid hydrolysis 
of orally administered pantethine is indicated by the 
lack of detectable serum pantethine in humans and rat 
and the concomitant rise in pantethine's metabolites 
(i.e. pantothenic acid and cysteamine). 
Statement of the Problem 
Pantethine reduces serum cholesterol levels in 
cholesterol-fed rabbits. The rapid hydrolysis of 
pantethine by serum pantetheinase results in high 
circulating levels of pantothenic acid and cysteamine 
and no measurable pantethine. It is possible that one 
of the hydrolysis products, pantothenate or cysteamine, 
produces the observed reduction in serum cholesterol 
levels. However, there have been no reports testing 
pantethine's metabolites for their hypocholesterolemic 
effect. 
Objectives 
The objective of this study is t6 examine the 
effects of pantethine and its metabolites on serum 
6 
cholesterol levels in cholesterol-fed rabbits. 
Currently there are few drugs which effectively treat 
hypercholesterolemia and those drugs which are 
available have side effects which interfer with 
compliance. Pantehine and its metabolites have few 
known side effects. If one of pantethine's hydrolysis 
products is an effective hypocholesterolemic agent, it 
may prove useful in clinically reducing high serum 
cholesterol levels. 
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REVIEW OF THE LITERATURE 
Coronary heart disease kills 550,000 Americans 
annually, making it the leading cause of death in the 
United States (Center for Disease Control, 1986). An 
estimated 5.4 million Americans have coronary heart 
disease (Levy, 1986). Depending upon the severity of 
coronary heart disease, the direct medical costs and 
indirect costs (loss of income) range from $4 to 
approximately $9000 per person (Oster and Epstein, 
1986). Atherosclerosis is the leading cause of 
myocardial and cerebral infarction which are the major 
causes of death from coronary heart disease (Ross, 
1986). The lesions of atherosclerosis are 
characterized by large lipid and cholesterol deposits; 
the cholesterol is usually found as cholesterol esters 
(Goldstein and Brown, 1977; Ross, 1986). This 
observation stimulates interest in the relationship of 
cholesterol to atherosclerosis and coronary heart 
disease. 
Epidemiological Studies 
The high cholesterol content of atherosclerotic 
lesions is only one factor linking cholesterol with 
with heart disease. High serum cholesterol levels are 
a major risk factor for developing coronary heart 
8 
disease (Wilhemset et al., 1973). Epidemiological 
studies indicate an increase in the incidence of 
coronary heart disease as serum cholesterol ris~s. 
The Framingham study, begun in 1949, prospectively 
analyzed coronary heart disease and hypertension in a 
group of 5,000 subjects. Subjects received biennial 
follow-up examinations which included a medical 
history, physical and laboratory tests including serum 
cholesterol levels. An eight year report of the 
Framingham Study (Kagan et al., 1962) noted that 
increased serum cholesterol levels correlated with an 
increased incidence of coronary heart disease; this 
risk was most pronounced in younger participants (40 to 
49 years at the beginning of the study) with total 
serum cholesterol levels over 260 mg/dl. High blood 
pressure, smoking and obesity also correlated with 
increased rates of cardiovascular disease. 
The Seven Countries Study (Keys, 1980) involved 
over 10,000 men from Finland, Greece, Japan, 
Yugoslavia, Italy, Netherlands, and the United States. 
These men were followed for 10 years to assess the 
relationship of blood pressure, serum cholesterol, 
smoking, activity level, weight, pulse rate, diet and 
respiratory function with coronary heart disease; only 
blood pressure and serum cholesterol were associated 
with an increased incidence of coronary disease. The 
9 
relationship between these variables and coronary heart 
disease was direct. Serum cholesterol levels 
correlated significantly with the ten year death rate 
from coronary heart disease (r = 0.8) and accounted for 
64% of variability among cohorts in death rate from 
coronary heart disease. This high correlation was also 
identified with non-fatal coronary heart disease 
(r = 0.79). 
The Pooling Project (Pooling Project Research 
Group, 1978) compiled and analyzed the results of five 
prospective studies on coronary problems. This 
retrospective study involved men aged 40 - 64 years and 
compared coronary heart disease rates at five quintiles 
of serum cholesterol (from < 194 mg/dl to > 268 mg/dl). 
The mean serum cholesterol levels of individuals with 
coronary disease was significantly higher than for 
those who were asymptomatic. The difference in means 
was most extreme at younger ages (19.7 mg/dl for 40 to 
44 years) and least for older groups (9.8 mg/dl for 50 
to 55 years). This relationship appears curvilinear 
with the risk of coronary heart disease rising 
dramatically in the upper quintiles. However, a recent 
study involving over 350,000 men found that the 
relationship between serum cholesterol and coronary 




Prospective studies identified high serum 
cholesterol levels as related to the development of 
coronary artery disease. Intervention studies attempt 
to assess the effect of varying treatments, including 
decreasing serum cholesterol levels, on individuals 
with symptomatic coronary heart disease. Recent 
clinical trials demonstrate the benefits of reducing 
serum cholesterol levels. 
The National Heart, Lung and Blood Institute 
a nalyzed the effect of diet and/or drug therapy on 
coronary arteriosclerosis in patients with 
hypercholesterolemia (Brensike et al., 1984). In this 
double-blind study, diet alone reduced serum 
cholesterol levels 11 3 ; use of cholestyramine with the 
diet dropped serum cholesterol levels a total of 31 3 . 
Coronary angiography of arterial lesion growth 
(measured by changes in lumen diameter) following five 
years of treatment showed that the diet group had 493 
progression of coronary artery disease versus only 353 
(p < 0.05) in those receiving both dietary and 
pharmacologic treatment. Cholestyramine decreased 
serum cholesterol levels and slowed the progression of 
coronary heart disease. 
The Lipid Research Clinics Corona~y Primary 
Prevention Trials (1984a, 1984b) analyzed the long term 
1 1 
benefits of drug therapy on serum lipids using the bile 
acid sequestrant cholestyramine. The clinics followed 
3,810 hypercholesterolemic men from the United States 
who were at high risk for coronary heart disease 
based upon serum lipid levels above the 95th percentile 
(265 mg/dl). All participants followed a cholesterol-
lowering diet and were assigned to either a 
cholestyramine or placebo treatment group. After ten 
years the cholestyramine group averaged cholesterol 
reductions of 13.4%; diet alone reduced serum 
cholesterol levels 8.5%. While there was no difference 
in total deaths between treatment groups, coronary 
heart disease death or non-fatal myocardial infarction 
decreased 19% with cholestyramine use. 
The Leiden Intervention Trial (Arntzenius et al., 
1985) analyzed the effect of a cholesterol-lowering 
diet on coronary lesion growth in 39 men with stable 
angina pectoris. Dietary modifications resulted in a 
10% decrease in cholesterol levels over a two year 
period. Lesion growth was assessed by angiography pre-
and post-treatment. Coronary lesion growth diminished 
significantly during this period and correlated with 
decreased serum cholesterol levels. 
Along with the correlation of serum cholesterol to 
coronary heart disease development in humans, animal 
studies indicate that increasing cholesterol levels 
coincide with the development of arterial lesions. 
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Rabbits and nonhuman primates show evidence of lipid 
accumulation in the arterial lumen begining at seven to 
ten days (Poole and Florey, 1958; Silkworth et al., 
1975; Faggiotto et al., 1984a; 1984b). The 
accumulation of lipid results in the formation of 
atherosclerotic plaques within 12 months of beginning 
the diet (Faggiotto et al., 1984b). 
Although high serum cholesterol levels have not 
been proven to cause coronary heart disease, the 
correlation is strong. On the basis of current 
13 
epidemiological and clinical data, the American Medical 
Association, National Institutes of Health and the American Heart 
Association (Consensus Conference, 1985; National 
Institutes of Health, 1985; American Heart Association, 
1984) recommend that the people of the United States 
actively try to reduce their risk factors for 
developing cardiovascular diseases. The 
recommendations include maintaining a desirable body 
weight and reducing serum cholesterol levels. 
While dietary modifications may suffice for the 
majority, the use of therapeutics may be needed for 
high risk individuals (Levy, 1980; Hoeg et al., 
1986). Aggressive treatment is recommended for those 
individuals with serum cholesterol levels above the 
90th percentile of the population; for men 35 years and 
older, 270 mg/dl represents the 95th percentile 
(Rifkind and Segal, 1983). 
Bile acid sequestrants and nicotinic acid provide 
the major form of drug therapy for hypercholesterolemic 
patients (Levy, 1980; Hunninghake, 1983; DeGraph, 
1984). These drugs have unpleasant side effects that 
may limit patient compliance. Probucol also lowers 
serum cholesterol levels, mainly through the reduction 
of LDL cholesterol levels (Levy, 1980; DeGraph, 1984). 
However, it is also associated with a decrease in HDL 
cholesterol levels. 
Pantethine and its Metabolites 
Pante thine 
The sulfhydryl of pantethine, pantetheine, is 
composed of the vitamin pantothenic acid and an 
aminothiol, cysteamine (see Figure 1). As part of 
Coenzyme A (CoA), the sulfhydryl moiety cysteamine is 
the active site of the molecule (Majerus et al., 1965; 
Pugh and Salih, 1965; Abiko, 1975). Because pantetheine 
can be synthesized in vitro from pantothenic acid and 
cysteine, it has not been identified as an essential 
nutrient. As the working arm of Coenzyme A and acyl 
carrier protein, pantetheine functions widely in the 
metabolism of carbohydrates, fat and proteins. 
Cholesterol synthesis directly involves pantetheine 
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of cholesterol begins with two units of acetyl CoA, and 
CoA involvement continues through the first three steps 
of cholesterol synthesis to the formation of 
mevalonate from hydroxymethylglutaryl CoA (Sabine, 
1977; Stryer, 1981). 
Pantothenic acid 
In 1933 Williams et al. (1933) first described and 
identified an essential growth factor for yeast which 
they named pantothenic acid (from the Greek meaning 
"everywhere"). The active agent in the chick anti-
dermatitis factor studied by Woolley and co-workers 
(1938, 1939) was also identified as pantothenic acid 
(Jukes, 1939). The discovery by Lipmann (1945) of a 
coenzyme of acetylation (CoA) and identification of 
pantothenate's biochemical role as part of CoA (Lipmann 
et al., 1947) provided a biochemical basis for 
pantothenic acid's biological function. Pantothenate 
exists in tissue in a bound form (e.g. as CoA 
pantethine,Acyl Carrier protein); very little is 
present in a free form (Novelli, 1953; Abiko, 1975). 
Blood and serum contain high levels of pantothenic acid 
(Wyse et al., 1985). Pantothenic acid in serum is 
present only in an unbound form, while pantothenate in 
erythrocytes mainly occurs in bound forms. 
While pantothenic acid is an essential nutrient, 
its ubiquitous distribution precludes widespread, 
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naturally occurring deficiencies. Deficiency has been 
experimentally induced in animals using pantothenate-
def icient diets (Unna, 1940; Schaefer et al., 1942). 
Pantothenic acid deficiency in humans can be caused by 
providing a deficient diet or a pantothenate antagonist 
(Bean and Hodges, 1954; Lubin et al., 1956; Hodges et 
al., 1957; 1959). Deficiency symptoms include 
decreased resistance to infection, malaise, changes in 
sensation such as paresthesia, irritability, 
alterations in insulin sensitivity and lesions of the 
skin, nervous system and adrenal glands (Novelli, 1953; 
Fox, 1984). Most of these symptoms are non-specific 
and are assumed to result from a wide-spread deficiency 
of CoA and other active forms of pantothenic acid that 
thus affect a variety of organ systems (Novelli, 1953; 
Abiko, 1975). 
Cysteamine 
Cysteamine, the sulfhydryl moiety of pantethine, 
has no known nutritional significance. Cysteamine is 
effective in treating acetaminophen overdose (Hamlyn et 
al., 1981). Cysteamine and its disulfide, cystamine, 
also afford short term protection against ionizing 
radiation such as x-rays (Bacq et al., 1953; Bacq and 
Alexander, 1964). This protective effect occurs only 
when administered prior to exposure. Eldjarn and 
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Nygaard (1954) found that the period of effectiveness 
corresponds to peak serum cysteamine/cystamine 
concentrations following administration. Serum 
cysteamine concentration rises rapidly following oral 
administration and returns almost to normal after 2 
hours (Eldjarn and Nygaard, 1954). The radioprotective 
action of thiols appears to be the result of rapid 
formation of mixed disulfides with proteins (Eldjarn 
and Pihl, 1956). 
Cysteamine (300 mg/kg) is used experimentally to 
induce duodenal ulcers in rats (Selye and Szabo, 1973; 
Man et al., 1984); a dose of 1 gm/kg in rats results in 
a 70% mortality rate within 48 hours (Selye and Szabo, 
1973). While the exact mechanism of ulcer formation is 
unknown, cystearnine administration is known to increase 
gastric acid output, pepsin activity, serum gastrin and 
to decrease gastric emptying time while altering the 
duodenal mucosa (Man et al., 1984). 
Cysteamine is used clinically to treat cystinosis. 
Cystinosis is a rare inherited disease characterized by 
cellular accumulation of free cystine (Schneider and 
Schulman, 1983; Rosenberg and Scriver, 1974). 
Deposition of cystine crystals in the eyes, bone 
marrow, leukocytes and soft tissues results in growth 
retardation, vitamin D-resistant rickets, anemia, 
photophobia and renal failure; prior to dialysis, most 
children with cystinosis died of renal failure. 
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Cysteamine/cystamine depletes cystinotic cells, both in 
vivo and in vitro, of free cystine (Thoene et al., 
1976; Yudkoff et al., 1981; Da Silva et al., 1985). 
Disulfide interchange of cysteine-cysteamine has been 
proposed as a depletion mechanism (Gahl ahd Bercu, 
1985; Gahl et al., 1985b). 
Rashes, lethargy, hyperthermia and hepatotoxicity 
are reported side effects of cysteamine treatment in 
cystinosis ( Corden et al. , 1981 ; Avner et al. , 1983). 
The report of hepatotoxicity is limited to a single 
case and may not be due to cysteamine treatment but 
rather to hepatic veno-occulusive disease that occurs 
with long-standing cystinosis (Gahl et al., 1983). The 
other adverse reactions occurred only with initial 
administration of high doses of cysteamine, and in all 
patients cysteamine was successfully readministered 
(Corden et al., 1981). Despite concerns about the 
possible side effects of cysteamine there have been few 
reports of adverse side effects at doses of 3 - 90 
mg/kg (Yudkoff et al., 1981; Da Silva et al., 1985; 
Schneider, 1985). 
Pantethine and Cholesterol 
Pantethine has been reported to alter lipid 
profiles in cholesterol fed humans and rabbits. The 
cholesterol-lowering effects of pantethine have been 
demonstrated in hyperlipidemic patients. Maggi and 
19 
colleagues (1982) studied the effect of pantethine 
treatment on hyperlipidemic patients who had showed 
limited response to low fat, low cholesterol diets. 
These patients complied with their diets and received 
900 mg of pantethine daily; there was no control group. 
Treatment was associated with a 203 decrease in total 
serum cholesterol levels after 90 days (p 0.01). 
Angelico and partners (1983) fed hyperlipidemic 
patients on a low fat diet for two weeks (baseline), 
and then provided either 1200 mg pantethine or a 
placebo to each patient (patients continued on the 
diet). The cross-over design included two 30-day test 
periods (placebo and pantethine). Pantethine treatment 
resulted in a 123 reduction in total serum cholesterol 
(p < 0.01 versus baseline levels, and a 333 decrease in 
serum triglycerides, but no changes in HDL cholesterol 
levels. 
Cattin and colleagues (1985) compared pantethine 
treatment with fenofibrate, a clofibrate analogue. Two 
groups of hypercholesterolemic patients received either 
fenofibrate or pantethine (900 mg/day) for 4 months; 
all patients consumed low fat diets. Both pantethine 
and fenofibrate resulted in a significant (p < 0.001) 
decrease in serum cholesterol levels after eight and 16 
weeks of treatment. Serum cholesterol levels decreased 
16 percent after 16 weeks of pantethine treatment 
versus 203 with fenofibrate. LDL cholesterol also 
20 
decreased significantly while HDL cholesterol remained 
unchanged. 
Both diabetes and kidney failure are associated 
with increased cholesterol levels. Pantethine 
treatment decreases serum cholesterol levels in 
hyperlipidemic diabetic patients (Miccoli et al., 
1984) and dialysis patients (Donati et al., 1986) 
treated with pantethine. In none of these studies 
were any adverse effects of pantethine treatment noted. 
Studies with rabbits also indicate that pantethine 
lowers serum cholesterol levels. Tomikawa and co-
workers (1982) fed three groups of rabbits diets of 
a) standard diet b) high cholesterol diet with 5% 
cholesterol) or c) the high cholesterol diet with 1% 
pantethine. Fasting blood samples were analyzed for 
lipid content using a density gradient. Total serum 
cholesterol and low density lipoprotein (LDL) 
cholesterol levels of pantethine supplemented rabbits 
began to decrease significantly after 10 days on the 
test diet. Cholesterol and LDL cholesterol levels 
reached their lowest levels (74% and 79%, respectively) 
after 14 days; these levels were maintained throughout 
the remaining 14 days of treatment. However, 
cholesterol levels in pantethine treated rabbits 
remained about four times those of control rabbits 
(103.5 mg/dl for the pantethine treated group vs 27.6 
21 
mg/dl for the high cholesterol group at day 14). Very 
low density lipoprotein cholesterol decreased 
significantly (p < 0.01) and high density lipoprotein 
cholesterol increased (p < 0.05). 
Carrara and colleagues (1984) confirmed these 
results and also noted a decrease in the severity of 
atherosclerotic lesion formation in the pantethine fed 
rabbits. New Zealand rabbits were placed into 
treatment groups similar to those used by Tomikawa; 
fasting blood samples were analyzed for cholesterol 
using enzymatic methods. In addition, samples of 
aortic tissue were studied for atherosclerotic lesion 
formation. While pantethine was found to lower serum 
cholesterol levels significantly (p < 0.01) when 
compared with cholesterol only rabbits, this decrease 
was not significant until after 65 days of treatment 
and was about 50% of cholesterol only rabbits. After 
90 days of treatment, pantethine resulted in a 65% 
decrease in total cholesterol levels (370 mg/dl vs 1050 
mg/dl). Visual analysis of aortic and coronary artery 
tissue indicated a lowering of lesion formation in 
pantethine fed rabbits, but total cholesterol content 
of these tissues did not differ from those of the 
cholesterol only group. 
A recent studied analyzed the dose-response effect 
of pantethine, compared pantethine treatment with the 
hypocholesterolemic drug probucol, and studied the 
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effect of combined treatment of probucol and 
pantethine on the serum cholesterol levels of 
hypercholesterolemic rabbits (Tawara et al., 1986). 
Pantethine was as effective as probucol in reducing 
serum cholesterol levels; probucol was associated with 
a decrease in HDL cholesterol levels while pantethine 
was not. Pantethine exhibited a dose-response 
relationship with serum cholesterol levels with 
reductions of 25%, 32% and 70% (0.25%, 0.5% and 0.75% 
pantethine supplementation, respectively) at nine 
weeks. Combined pantethine and probucol treatment 
resulted in lower cholesterol levels than either drug 
achieved separately and resulted in higher HDL levels 
than did probucol treatment alone. 
Studies on fibroblasts show a reduction in 
cholesterol synthesis with pantethine. Ranganathan and 
colleagues (1982) incubated human skin fibroblasts with 
pantethine; incorporation of radiolabled acetate or 
mevalonolactone into sterols was measured. Pantethine 
incubation resulted in a 50% to 80% decrease in 
cholesterol synthesis (as measured by uptake of 
radiolabled precursors) and a simultaneous increase in 
intermediate methyl sterols; the magnitude of 
pantethine's effect was dose related. Other sulfur-
containing compounds (dithiothreitol, glutathione, CoA, 
and cystine) did not reduce cholesterol synthesis. 
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The mechanism of pantethine's hypercholesterolemic 
action is unknown. Because of pantethine's role in 
Coenzyme A and acyl carrier protein, changes affecting 
lipid metabolism and cholesterol levels may occur 
through alterations involving these compounds. 
However, pantetheine is hydrolyzed to pantothenic 
acid and cysteamine by a specific enzyme, 
pantetheinase, (Wittwer et al, 1983; Abiko, 1975) and 
may not remain intact long enough to result in a 
therapeutic effect. 
Pantetheinase is specific for pantetheine and is 
inhibited by high concentrations of pantothenate 
(Abiko, 1975; Wittwer et al., 1983). Pantetheinase has 
been purified from horse kidney (Dupre and Cavallini, 
1979), rat liver and kidney (Abiko, 1975), and pig 
kidney (Wittwer et al., 1983). Pantetheine-hydrolyzing 
activity was noted in rat and human intestinal tissue 
(Wittwer et al., 1985). The level of pantetheinase 
activity in intestinal tissue appears to be sufficient 
to ensure nearly complete hydrolysis of pantethine 
during absorption (Shibata et al., 1983; Wittwer et 
al., 1983). 
Evidence of plasma pantetheine-hydrolyzing activity 
exists in rats and humans (Ono et al., 1974; Wittwer et 
al., 1985). Blood samples from rats taken 30 minutes 
after intravenous administrations of pantethine showed 
over 50% present as free pantothenic acid, indicating 
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rapid hydrolysis of the injected dose. In cystinotic 
patients fed pantethine (70 - 1000 mg/kg/day), no serum 
pantethine was detected at any time after 
administration. However, serum levels of pantothenic 
acid and cysteamine increased dramatically (Wittwer et 
al., 1985). The authors also noted a 14% drop in serum 
cholesterol levels after two weeks of pantethine 
treatment. 
The rapid hydrolysis of pantethine by pantetheinase 
leads to speculation that one of the hydrolysis 
products, rather than pantethine itself, may be the 
active hypercholesterolemic compound. 
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METHODOLOGY 
Pantethine reduces serum cholesterol levels in both 
cholesterol-fed animals and hypercholesterolemic 
humans. Pantethine is rapidly hydrolyzed to its 
component metabolites, pantothenic acid and cysteamine, 
by the enzyme pantetheinase. It is hypothesized that 
one of these metabolites rather than pantethine 
produces the reported hypocholesterolemic effect. This 
study is designed to compare the effect of pantethine 
with the effects of pantothenic acid and cysteamine on 
serum cholesterol levels in hypercholesterolemic 
rabbits. To provide easy comparison, the experimental 
design is similar to that used by Tomikawa and 
colleagues (1982) in researching the effect of 
pantethine in experimentally hypercholesterolemic 
rabbits. 
Experiment 1: Comparison of Pantethine, Cystamine 
and Pantothenic Acid on Serum Cholesterol in 
Cholesterol-Fed Rabbits 
Fourteen male New Zealand white rabbits weighing 
2.0 to 2.5 kg (4 to 6 weeks) were ordered from local 
suppliers. The number of rabbits in the study was 
limited by the space available at the Utah State 
University Lab Animal Research Center. 
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All rabbits were fed a high cholesterol diet. The 
cholesterol only group served as a control for 
cholesterol levels; the pantethine group served as 
reference group to compare the effect of pantothenic 
acid and cystamine. The rabbits were placed in one of 
four treatment groups: cholesterol, pantethine, 
pantothenic acid, and cystamine (the disulfide of 
cysteamine). The rabbits were divided into treatment 
groups by taking the four rabbits with the highest pre-
treatment serum cholesterol levels (individual serum 
cholesterol level reported in Appendix 1) and randomly 
assigning them to one of the four treatment groups. 
This procedure was repeated with the rabbits having the 
four lowest serum cholesterol levels; the remaining 
rabbits were then randomly assigned to treatment 
groups. 
Diets were custom made by ICN Nutritional 
Biochemicals (Cleveland, OH) and consisted of Purina 
Rabbit Chow with 0.5% cholesterol (supplied by ICN 
Biochemicals), 1% by weight pantethine or an equimolar 
amount of cystamine, or pantothenic acid (all purchased 
from Sigma Chemical Co., St. Louis, MO.). The rabbits 
were fed 150 g of food daily and residual food (if any) 
was weighed; water was supplied ad lib. Rabbits were 
housed and cared for in the Lab Animal Research Center. 
Fasting blood samples were drawn weekly for 
analysis of total serum cholesterol levels. Serum 
cholesterol levels were measured by the colorimetric 
method of Allain and co-workers (1974). This enzymatic 
procedure couples the hydrolysis and oxidation of 
cholesterol esters with a chromogenic system to produce 
a dye with a maximum absorbance at 500 nm. This 
determination employs the following reactions: 
1) Cholesterol Esters Cholesterol esterase 
Cholesterol + Fatty Acids 
2) Cholesterol + o2 
Cholesterol 
Oxidase 
Cholest-4-en-3-one + H2o2 
3) + 4-Aminoantipyrine + 
p-Hydroxybenzene-sulfonate 
Peroxidase Quinoneimine Dye + 4H2o 
All reagents and standards were purchased as a kit 
from Sigma Chemical Co. (Cleveland, OH). The 
cholesterol assay is outlined in Table 1. Absorbance 
was measured using a Gilford 240 spectrophotometer. 
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Table 1: Procedures for total serum cholesterol 
assay. 
Reagent Blank Control Test Sample 
dH20 10 ul 
standard 10 ul 
sample 10 ul 
Cholesterol 
Reagent 1. 0 ml 1. 0 ml 1.0 ml 
Mix and incubate at 37°c for 10 minutes. 
Read A500 using the blank as a reference. 
Total serum cholesterol was calculated using the 
following formula: 
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Total cholesterol (mg/dl) = A500 test 
A500standard 
X [standard] 
In this study, the relationship between the absorbance 
at 500 nm and total serum cholesterol showed a linear 
relationship up to a concentration of 800 mg/dl. 
Serum lipoprotein separation was performed prior to 
treatment and after 5 weeks. The separation was 
carried out using the density gradient method of Hinton 
et al. (1974); this method does not separate high 
density lipoproteins. 
Chylomicrons were removed after centrifuging at 
15,000 r.p.m. for 180 minutes (Nelson, 1972) using a 
Beckman model J-21C preparative centrifuge and a JA-20 
rotor (Beckman Instrument Co., Palo Alto, CA). 
Serum samples were adjusted to a density of 1.22 by 
adding 0.32 g/ml of solid NaBr. Three stock solutions 
were prepared as follows: A) 11.4 g NaCl+ 0.1 g 
EDTA/L, d = 1.003; B) 263 g NaBr + 11.4 g NaCl+ 0.1 g 
EDTA/L, d = 1.205; C) 582 g NaBr/L, d = 1.424. All 
chemicals were purchased from Aldrich Chemical Co. 
(Milwaukee, WI.). To form the density gradient, 0.7 ml 
of solution C was placed in a 12.6 ml nitrocellulose 
ultracentrifuge tube (Beckman Instrument Co.) and 0.7 
ml of density adjusted plasma was layered on top. 
Linear density gradients were formed using 5.6 ml each 
of solutions A and B. 
The density gradients were centrifuged at 30,000 
r.p.m. for 2 hours in a Beckman model L3-50 preparative 
ultracentrifuge using a SW-41 swinging bucket rotor. 
The density gradients were analyzed using a Beckman 
Fraction Recovery System and Isco absorbance monitor 
model UA-4 (Isco Instrument Specialties Co., Lincoln, 
NE.) at A240 • There was no quantitative analysis 
performed on the separated fractions. 
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Experiment 2: Comparison of Pantethine, Cystamine, 
Cysteamine, and 2-Hydroxyethyl Disulfide 
on Serum Cholesterol in 
Cholesterol-Fed Rabbits 
A second experiment was performed to compare the 
effects of other low-molecular weight thiols on serum 
cholesterol levels in hypercholesterolemic rabbits. 
The disulfide forms of the following thiols were used: 
cysteamine (cystamine), cysteine (cystine), 2-
mercaptoethanol (2-hydroxyethyl disulfide); all 
chemicals were purchased from Aldrich Chemical Co. 







Figure 2: Structures of cysteamine, cysteine, 
and 2-mercaptoethanol. 
The experimental design was similar to that used in 
the first experiment. Sixteen male New Zealand White 
rabbits weighing 1.8 to 2.0 kg (4 to 6 weeks) were 
obtained from R & R Rabbitry (Stanwood, WA). The 
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rabbits included four sets of littermates. The rabbits 
were divided into groups so that there was one member 
of each litter per group. Baseline cholesterol levels 
were obtained on each rabbit. 
Four treatment groups, with four rabbits per group, 
were established as follows: cholesterol, cystamine, 
cystine, 2-hydroxyethyl disulfide. Treatment groups 
were fed a 0.5% cholesterol diet supplemented 
with molar equivalents of one of the test compounds at 
levels equal to 1% pantethine. Total serum cholesterol 
levels were analyzed using the assay previously 
described; serum cholesterol concentrations were 
calculated from a standard curve run with the serum 
samples. Lipoprotein separation was not performed. 
Analysis of Data 
Weekly, individual cholesterol levels were averaged 
within treatment groups. Analysis of variance to test 
for significance among mean treatment cholesterol 
levels was conducted weekly using Minitab Statistical 
Package (Pennsylvania State University, University 
Park, PA) according to the following model: 
Y .. = T . + e .. 
lJ l lJ 
where Y .. is cholesterol level for each observation, T. 
lJ l 
it the variation associated with each treatment, and 
e .. is variation due to individua l differences. lJ 
For any week in which significant differences among 
means were found, treatment means were analyzed for 
least significant differences using the Fisher Least 
Significant Difference test (Ott, 1977) to determine 




The purpose of this study was to compare the effect 
of pantethine and its metabolites, pantothenic acid and 
cysteamine, on serum cholesterol levels in 
hypercholesterolemic rabbits. The results of a second 
experiment comparing the effects of small thiols on 
serum cholesterol levels are also reported. 
Experiment 1: Comparison of Pantethine, Cystamine 
and Pantothenic Acid on Serum Cholesterol in 
Cholesterol-Fed Rabbits 
All experimental diets were well tolerated, with 
each group consuming an average of 150 gm/day; this 
provided 750 mg cholesterol per day and 1500 mg 
pantethine, 600 mg cystamine or 1300 mg pantothenic 
acid daily. All rabbits gained weight during the test 
period. Analysis of variance on the serum cholesterol 
levels of treatment means showed a significant 
difference (p < 0.005) after three weeks of 
supplementation (Figure 3). Treatment means were 
analyzed for least significant differences. This 
analysis indicated that cystamine and pantethine 
supplemented groups were significantly different from 
the cholesterol only and pantothenic acid groups (p < 
0.05). Serum cholesterol levels in the pantethine and 
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Figure 3: Total serum cholesterol response of 
cholesterol-fed rabbits to pantethine 
and its metabolites. 
(*, p < 0.05; **, p < 0.005). 
3 .5 
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cystamine fed rabbits were reduced an average of 21 % 
and 30%, respectively when compared to the cholesterol 
only group (Table 2). 
Table 2: Total serum cholesterol levels (mg/dl) 
by treatment group--Experiment 1 
(mean+ standard deviation). 
Week Group 
Cholesterol Pantethine Pantothenate Cyst amine 
x SD x SD x SD x SD 
0 70 18 75 18 71 14 63 16 
1 383 83 249 98 292 78 300 157 
2 728 74 555 125 694 122 571 140 
3 815 1 1 582 79 782 75 630 62 
4 1017 76 778 186 1144 91 800 198 
5 1121 81 864 205 1264 120 806 235 
Serum lipoprotein separation indicated a marked 
increase in the the level of very low density, 
intermediate density and low density lipoproteins with 
cholesterol feeding; the increase in intermediate 
density lipoproteins was most pronounced. An example 
of the changes seen in serum lipoprotein fractions pre-
and post treatment is presented in Figure 4. There 
appeared to be no noticeable difference in lipoprotein 
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Figure 4: Pre- ( ......... 1 and post-treatment (-) serum 
lipoprotein profiles of cholesterol treated 
rabbits. 
Experiment 2: Comparison of Cystamine, Cystine, 
and 2-Hydroxyethyl Disulfide on 
Serum Cholesterol 
The significant reduction in serum cholesterol 
levels with cystamine supplementation led to 
speculation regarding the specificity of this thiol in 
reducing serum cholesterol levels. A second experiment 
was conducted comparing cystamine with the disulfides 
of two structurally similar, low-molecular weight 
thiols, cystine and 2-hydroxyethyl disulfide. 
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The 2-hydroxyethyl disulfide diet was not as well-
accepted as the other diets. In order to avoid any 
differences in serum cholesterol levels due to food 
intake, all groups were fed to match the intake of the 
2-hydroxyethyl group. The average intake was 110 
gm/day, resulting in a total of 550 mg cholesterol 
daily and either 450 mg cystamine, 480 mg cystine or 
300 mg of 2-hydroxyethyl disulfide. This intake level 
resulted in a 27% decrease in cholesterol and 
supplement intake compared with that of experiment 1. 
There were no adverse effects noted from any of the 
diets. 
None of the test compounds significantly reduced 
serum cholesterol levels, nor did cystamine treatment 
significantly reduce cholesterol levels. There was 
considerable variation within the groups that may have 




Table 3: Total serum cholesterol levels (mg/dl) by 
treatment group--Experiment 2 (mean + 
standard deviation). 
Week Group 
Cholesterol Cyst amine Cystine 2,Hydroxyethyl 
x SD x SD x SD x SD 
0 60 12 60 8 60 4 78 49 
1 254 186 249 290 221 141 308 183 
2 545 290 410 60 496 280 538 284 
3 773 286 563 45 742 326 655 172 
4 660 264 610 223 750 254 670 172 
5 1155 305 964 186 1258 392 1053 231 
6 1393 326 1078 141 1304 344 1239 197 
7 1276 222 1118 179 1294 367 1548 211 
The serum cholesterol levels of the control group 
were similar to those of experiment 1 after five weeks 
of treatment; however, at week five, the cystamine 
group had serum cholesterol levels 20% higher than in 
experiment 1. Despite the lack of significant 
reductions, cholesterol levels in the cystamine treated 
group tended to be lower than for the other groups 
(Figure 5). There was no significant difference in 
serum cholesterol levels among the litters (Figure 6). 
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Figure 5: Total serum cholesterol response of 
cholesterol-fed rabbits to cystamine, cystine, 
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Figure 6: Total serum cholesterol response of cholesterol-
fed rabbits by litters--Experiment 2. 
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DISCUSSION 
Many researchers have identified pantethine as an 
effective hypocholesterolemic agent; however, there 
have been studies reported in which pantethine did not 
significantly reduce serum cholesterol levels. A study 
comparing pantethine to tiadenol (a hypocholesterolemic 
drug) treatment found that pantethine treatment did 
not reduce total serum cholesterol nor LDL cholesterol 
levels in 30 hypercholesterolemic patients (Da Col et 
al., 1984). 
Rubba and colleagues compared the effectiveness of 
short-term (1 month) treatment of pantethine versus 
fenofibrate (1985). They found that while fenofibrate 
treatment resulted in significant reductions in serum 
cholesterol levels, pantethine treatment lowered serum 
cholesterol levels a non-significant 43 . 
Other researchers have noted significant decreases 
with pantethine treatment of some serum lipid 
fractions, namely triglycerides and VLDL cholesterol, 
but not in total serum cholesterol (Maggi et al., 
1982). 
The cholesterol-lowering effect of pantethine in 
cholesterol-fed rabbits was confirmed in this study, 
although the reductions were considerably less than 
those reported by Tomikawa et al. (1982). However, in 
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experiment 1, cystamine, a metabolite of pantethine, 
provided a reduction of serum cholesterol levels 
similar to that of pantethine. Pantothenate did not 
lower serum cholesterol levels. The second experiment 
was inconclusive regarding the specificity of 
cysteamine's action. 
In experiment 2, cysteamine did not have the same 
hypocholesterolemic response as in experiment 1. This 
may be due to different chemical sources (Sigma vs. 
Aldrich) or to the wide variation within treatment 
groups. It is also possible that the decreased food 
intake in experiment 2, and the concomitant decrease in 
cystamine intake, may have lowered the given dose to a 
non-therapeutic level. Figure 7 compares the average 
serum cholesterol levels of rabbits fed 750 mg 
cholesterol/day (experiment 1) versus 550 mg 
cholesterol/day (experiment 2) averaged across the 
cholesterol only and cystamine groups during the first 
5 weeks of treatment. These two treatments occurred in 
both experiments and provide an indication of the 
response of serum cholesterol levels to changes in the 
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Figure 7: Weekly total serum cholesterol levels of 
rabbits fed 750 mg cholesterol/day 
(Experiment 1) or 550 mg cholesterol / day 
(Experiment 2). 
The response to any drug is dependent upon dose. 
It the level is too low, there is no response; if it is 
too high, there is an unwanted or toxic response 
(Roberts, 1982; Gibaldi, 1984). The effective dose is 
based upon many interrelated variables of 
pharmacodynamics and pharmacokinetics (Gibaldi, 1984). 
Some hypocholesterolemic drugs, such as cholestyramine, 
show a graded response beginnning at even low doses 
(DeGraph, 1984). However, nicotinic acid only begins 
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to effectively reduce cholesterol levels at 50 - 500 
times the recommended vitamin requirements (Hodges and 
Smith, 19 84) • 
Pantethine treatment has shown a dose-response 
relationship in some studies. Tawara and colleagues 
(1986) compared the effect of varying doses of 
pantethine on serum cholesterol levels and found that 
the response was dose related. A dose of 0.25% 
pantethine resulted in a 25% decrease in serum 
cholesterol levels versus a 32% decrease at a dose of 
0.5%. Ranganathan et al. (1982) found a similar 
relationship for pantethine on cholesterol synthesis of 
human skin fibroblasts. 
The hypocholesterolemic effect of pantethine has 
been attributed to alterations in CoA levels. CoA 
shunts acetate molecules into either the tricarboxylic 
acid cycle (TCA cycle) for oxidation or into lipid and 
sterol synthesis (Maggi et al., 1982; Gaddi et al., 
1984). If increased CoA preferentially shifted acetate 
into the TCA cycle and away from lipid and cholesterol 
synthesis, then cholesterol levels would be lowered. 
CoA can be synthesized from pantothenic acid; or 
pantetheine, through direct phosphorylation, can bypass 
the first three steps in CoA biosynthesis and rapidly 
increase CoA levels in vitro (Shimizu and Abiko, 1965; 
Abiko, 1975). In view of the presence of pantetheinase 
45 
activity in serum, pantethine may not enter the CoA 
biosynthetic pathway intact; it may be hydrolyzed to 
pantothenic acid prior to CoA biosynthesis. However, 
in this study pantothenic acid had no effect on serum 
cholesterol levels, indicating some mechanism other 
than increased levels of CoA may be responsible for the 
hypocholesterolemic effect of pantethine. 
The mechanism of pantethine's effect on serum 
cholesterol is unknown. Shinomiya and co-workers 
(1980) found that cholesterol esterase activity 
increased in rat arterial walls on a high cholesterol, 
pantethine supplemented diet when compared with an 
unsupplemented diet. Cholesterol esterase hydrolyzes 
cholesterol esters, the cellular storage form of 
cholesterol, following binding to lipoprotein receptors 
and uptake by cells. Increasing cholesterol esterase 
activity helps remove circulating cholesterol and 
decrease serum cholesterol levels. 
Pantethine inhibits cholesterol synthesis in vitro. 
Incorporation of radiolabled acetate into cholesterol 
markedly decreases in human skin fibroblasts incubated 
with pantethine (Ranganathan et al., 1982). The 
inhibition occurs in the conversion of lanosterol to 
cholesterol; there are several intermediate steps in 
this conversion and the exact point of inhibition is 
unknown. The effect of other sulfur-containing 
compounds (dithiothreitol, glutathione, and cystine) 
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were compared with pantethine and had no effect on 
cholesterol biosynthesis; cystamine was not tested. 
The hypocholesterolemic effect of pantethine and 
cysteamine may result from the effect of 
thiol:disulfide exchanges on enzyme systems. Ziegler 
(1985) states that thiol:disulfide exchange may alter 
enzyme activity and serve to regulate enzyme activity. 
One enzyme system in which this mechanism appears to 
work is 3-hydroxy-3-methylglutaryl-CoA (HMGCoA) 
reductase. HMGCoA catalyzes the first committed step in 
the biosynthesis of cholesterol by reducing HMGCoA to 
mevalonate. Gilbert and Stewart (1981) found that 
thiols such as HMGCoA and CoA rapidly inactivate HMGCoA 
reductase. Activity can be restored with 
dithiothreitol. Dithiothreitol inhibits disulfide 
formation, so these researchers speculate that 
disulfide formation may be responsible for inactivation 
of HMGCoA reductase. The effect of cystamine on HMGCoA 
reductase has not been studied. 
Familial dysbetalipoproteinemia (familial Type III 
lipoproteinemia) is characterized by increased levels 
of very low density and intermediate density 
lipoproteins (Havel et al., 1980). Clearance of 
chylomicrons and very low density lipoproteins is 
impaired and leads to an increase in cholesterol-rich 
remnant particles (Hazzard and Bierman, 1976; Chait et 
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al., 1978; Havel, 1982). Cholesterol-fed rabbits, 
including the cholesterol treated rabbits in this 
study, exhibit similar increases in very low density 
and intermediate density lipoproteins (Shore et al., 
1974; Kushwaha and Hazzard, 1978). Ross and Zilversmit 
(1977) found that increased chylomicron remnants 
constituted the majority of these lipoproteins. 
While cholesterol-fed rabbits exhibit a lipoprotein 
profile similar to that in Type III 
hypercholesterolemia, the mechanism of increased 
cholesterol levels differ. Hypercholesterolemic 
rabbits result not from alterations in apoprotein E, 
but from saturation of hepatic lipoprotein receptors 
and a simultaneous decrease in the number of hepatic 
lipoprotein receptors (Kita et al., 1981; Kovanen et 
al., 1981). The mechanism of the hypocholesterolemic 
observed in rabbits may not be the same as that 
observed in humans. 
Humans with familial dysbetalipoproteinemia 
(familial Type III hyperlipidemia) possess a variation 
in apolipoprotein E which is needed for recognition of 
remnant particles by hepatic lipoprotein receptors. 
The alteration in apoprotein E reduces recognition, 
binding and uptake of very low density lipoprotein 
remnants by hepatic cells and results in greatly 
increased serum cholesterol levels (Havel, 1982). 
The varient apoprotein E in Type III 
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hyperlipoproteinemia, i.e apolipoprotein E2, results from a 
cysteine for arginine substitution at residues 112 and 
158 (Weisgraber et al., 1981). Another form, 
apoprotein E3, has one cysteine for arginine 
substitution at residue 112. These substitutions 
result in altered lipoprotein charges and are 
associated with decreased in binding to LDL receptors 
(Schneider et al., 1981), with apoprotein E2 showing 
the most dramatic decrease in binding capacity. 
Cysteamine and cystamine have been proposed as 
hypocholesterolemic agents for patients with familial 
dysbetalipoproteinemia (Fisher and Gahl, 1982; 
Weisgraber et al., 1982; Hui et al., 1984; Innerarity 
et al., 1984; Gahl et al., 1985a). Cysteamine and 
cystamine alter the charge on apolipoprotein E in vitro 
by forming a mixed disulfide with cysteine and 
converting it to a lysine analogue (Fisher and Gahl, 
1982; Weisgraber et al., 1982; Rall et al., 1983). 
Cysteamine treatment increases LDL receptor binding 
activity but does not return binding capacity to normal 
levels. Innerarity et al. (1984) confirm the increased 
receptor binding of apoprotein E2 with cysteamine 
treatment but note that the increased activity is 
retained following reversal of the charge modification. 
Positive charge may not be the only cause of improved 
binding activity. 
Alteration of defective apolipoproteins with 
cysteamine in serum from Type III hyperlipidemic 
patients suggests a possible mechanism for cysteamine's 
hypolipidemic effect in rabbits, but, to date, the 
effect of cysteamine treatment in patients with Type 
III hyperlipoproteinemia or with other types of lipid 
disorders has not been studied, 
Another possible mechanism for cystamine's 
hypocholesterolemic action is through alterations in 
hormone regulation. Cystamine treatment in rats is 
associated with alterations of some hormones. 
Cysteamine depletes tissues of somatostatin (Seiler et 
al., 1983; Szabo and Reichlin, 1985) and lowers the 
noradrenaline of the hypothalmus in rats (Vecsei et 
al., 1985). Cystinotic children receiving cysteamine 
show altered prolactin response (Millard et al., 1982). 
Conclusions 
Pantethine and cystamine appear equally effective 
at lowering serum cholesterol levels in 
hypercholesterolemic rabbits. Current reseach on the 
use of pantethine has not considered its metabolites as 
possible hypocholesterolemic agents. In view of 
results presented in this study, previous research 
designs should be repeated on animals and 
hyperlipidemic patients using cystamine as one test 
agent. Of particular interest would be studies 
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involving the effect of pantethine and cystamine 
treatment in patients with Type III 
hyperlipoproteinemia. The possibility of a dose-
related response for cystamine also needs further 
testing. 
Possible cholesterol-lowering mechanisms for 
cysteamine include inhibition of HMGCoA, alterations in 
apoprotein levels or binding capacity, or changes 
occurring through endocrine regulation. 
Cysteamine's major physiological actions result 
from its ready ability to form mixed disulfides with 
many compounds. Future research into cystamine's 
hypocholesterolemic action might focus on the formation 
of disulfides as a possible mechanism. 
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Appendix .l..:.. Serum Cholesterol Levels of 
Individual Rabbits by Group--
Experiment 1. 
Cholesterol Only Group 
Rabbit 
6 7 12 Average 
x SD 
87 57 72 70 18 
463 298 388 383 83 
813 691 680 728 74 
827 811 807 815 1 1 
1104 980 966 1017 76 
1214 1069 1079 1121 81 
Pantethine Group 
Rabbit 
3 4 5 11 Average 
x SD 
131 63 47 60 75 18 
372 174 165 283 249 98 
735 516 447 521 555 125 
663 634 530 501 582 79 
1038 746 730 598 778 186 
1155 861 734 706 864 205 
65 
Pantothenic Acid Group 
Week Rabbit 
2 8 10 15 Average 
x SD 
0 66 58 69 90 71 14 
1 351 228 368 221 292 78 
2 749 629 835 561 694 122 
3 856 763 824 685 782 75 
4 1270 1124 1127 1054 1144 91 
5 1379 1328 1106 1241 1264 120 
C~stamine Group 
Week Rabbit 
9 13 14 Average 
x SD 
0 48 62 80 63 16 
1 235 186 479 300 157 
2 456 529 727 571 140 
3 578 613 695 630 62 
4 699 1028 672 800 198 
5 667 1077 673 806 235 
67 
Appendix ~ Serum Cholesterol Levels of 
Individual Rabbits by Treatement 
Groups--Experiment ~ 
Cholesterol Only Group 
Week Rabbit 
1 5 6 13 Average 
x SD 
0 45 65 75 50 60 12 
1 190 305 40 480 254 186 
2 260 720 340 860 545 290 
3 420 990 660 1020 773 286 
4 430 1030 660 520 660 264 
5 900 1540 920 1260 1155 305 
6 1265 1865 1120 1320 1393 326 
7 1120 1560 1080 1345 1276 222 
Cl'.:stamine Group 
Week Rabbit 
2 7 9 14 Average 
x SD 
0 60 70 50 60 60 8 
1 275 235 265 220 249 26 
2 340 380 460 460 410 60 
3 510 600 600 540 563 45 
4 440 480 590 930 610 223 
5 760 1025 1190 880 964 186 
6 960 1095 1270 985 1078 141 
7 960 1070 1375 1065 1118 179 
Cystine Group 
Week Rabbit 
4 8 1 1 15 Average 
x SD 
0 60 55 60 65 60 4 
1 400 130 265 90 221 141 
2 900 360 460 280 496 280 
3 1080 960 720 400 742 326 
4 910 960 720 400 750 254 
5 1560 1520 1240 710 1258 392 
6 1480 1560 1375 800 1304 344 
7 1680 1400 1295 800 1294 367 
2 2 Hrctroxrethrl Group 
Week Rabbit 
3 10 12 16 Average 
x SD 
0 50 60 50 150 78 49 
1 35 420 400 375 308 183 
2 200 550 880 500 538 284 
3 480 390 1150 600 655 341 
4 630 530 920 600 670 172 
5 950 820 1360 1080 1053 231 
6 1265 985 1465 1240 1239 197 
7 1360 1375 1775 1680 1548 211 
